Mineralys Gets a Mid-Stage Win in Hypertension Patients with Poor Renal Function

Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps - Mineralys Therapeutics (NASDAQ:MLYS)

Mineralys reports Phase 2 trial success for lorundrostat, showing BP and kidney improvements in CKD patients with favorable safety results.

Mineralys gets a mid-stage win in hypertension patients with poor renal function

Mineralys Therapeutics said Tuesday that its blood pressure med lorundrostat has succeeded in a Phase 2 trial in subjects with hypertension and comorbid chronic kidney disease (CKD). The data will be added to a planned ...